Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRPHNASDAQ:IMTXNASDAQ:LENZNASDAQ:REPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRPHGraphite Bio$13.89$2.01▼$4.26$185.20M0.2282,405 shs435,164 shsIMTXImmatics$5.46+0.4%$5.18$3.30▼$13.09$661.23M0.83671,328 shs679,715 shsLENZLENZ Therapeutics$29.52-0.9%$28.33$16.28▼$38.93$838.19M0.42189,257 shs294,487 shsREPLReplimune Group$9.45-3.1%$8.95$6.44▼$17.00$751.60M0.63857,223 shs1.27 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRPHGraphite Bio0.00%0.00%0.00%0.00%0.00%IMTXImmatics+0.37%-6.67%+6.85%+15.92%-54.50%LENZLENZ Therapeutics-0.87%-1.70%+4.79%+11.27%+66.87%REPLReplimune Group-3.08%-0.42%+13.17%-9.57%+7.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGRPHGraphite BioN/AN/AN/AN/AN/AN/AN/AN/AIMTXImmatics2.6974 of 5 stars3.63.00.00.03.21.70.0LENZLENZ Therapeutics1.3785 of 5 stars3.61.00.00.01.40.80.0REPLReplimune Group4.3743 of 5 stars3.63.00.04.52.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRPHGraphite Bio 0.00N/AN/AN/AIMTXImmatics 3.20Buy$14.67168.62% UpsideLENZLENZ Therapeutics 3.17Buy$46.6057.86% UpsideREPLReplimune Group 3.13Buy$20.83120.46% UpsideCurrent Analyst Ratings BreakdownLatest GRPH, LENZ, REPL, and IMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025REPLReplimune GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight6/2/2025REPLReplimune GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $22.005/28/2025IMTXImmaticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.005/8/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/16/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/14/2025LENZLENZ TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$38.00 ➝ $51.004/1/2025IMTXImmaticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRPHGraphite BioN/AN/AN/AN/A$3.15 per shareN/AIMTXImmatics$168.65M3.94$0.25 per share22.26$5.12 per share1.07LENZLENZ TherapeuticsN/AN/AN/AN/A$7.42 per shareN/AREPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRPHGraphite Bio-$124.65M-$2.23N/AN/AN/AN/A-33.12%-27.96%N/AIMTXImmatics$16.47M-$0.17N/AN/AN/A-14.73%-4.52%-3.34%8/12/2025 (Estimated)LENZLENZ Therapeutics-$49.77M-$1.77N/AN/AN/AN/A-23.74%-22.65%8/13/2025 (Estimated)REPLReplimune Group-$247.30M-$3.07N/AN/AN/AN/A-57.98%-45.21%8/6/2025 (Estimated)Latest GRPH, LENZ, REPL, and IMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q4 2025REPLReplimune Group-$0.75-$0.82-$0.07-$0.82N/AN/A5/13/2025Q1 2025IMTXImmatics-$0.39-$0.35+$0.04-$0.35$14.92 million$20.12 million5/7/2025Q1 2025LENZLENZ Therapeutics-$0.55-$0.53+$0.02-$0.53N/AN/A3/27/2025Q4 2024IMTXImmatics-$0.03$0.48+$0.51$0.48$16.16 million$15.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGRPHGraphite BioN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRPHGraphite BioN/A39.2039.20IMTXImmaticsN/A10.2810.28LENZLENZ TherapeuticsN/A23.0923.09REPLReplimune Group0.177.957.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRPHGraphite Bio54.32%IMTXImmatics64.41%LENZLENZ Therapeutics54.32%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipGRPHGraphite Bio38.40%IMTXImmatics3.30%LENZLENZ Therapeutics6.90%REPLReplimune Group8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRPHGraphite Bio658.24 million35.87 millionNot OptionableIMTXImmatics260121.55 million117.54 millionOptionableLENZLENZ Therapeutics11028.15 million26.20 millionN/AREPLReplimune Group21077.09 million70.30 millionOptionableGRPH, LENZ, REPL, and IMTX HeadlinesRecent News About These CompaniesReplimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Buy" by AnalystsJune 25 at 4:26 AM | marketbeat.comCantor Fitzgerald Begins Coverage on Replimune Group (NASDAQ:REPL)June 22, 2025 | americanbankingnews.comCantor Fitzgerald Initiates Coverage of Replimune Group (REPL) with Overweight RecommendationJune 20, 2025 | msn.comReplimune Group (NASDAQ:REPL) Coverage Initiated at Cantor FitzgeraldJune 20, 2025 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Shares Sold by Bank of America Corp DEJune 14, 2025 | marketbeat.comReplimune Group, Inc. Grants Inducement Equity Awards to New Employees Under 2025 PlanJune 6, 2025 | quiverquant.comQReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comReplimune Group (NASDAQ:REPL) Shares Gap Up - Time to Buy?June 4, 2025 | marketbeat.comWellington Management Group LLP Grows Position in Replimune Group, Inc. (NASDAQ:REPL)June 3, 2025 | marketbeat.comPiper Sandler Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock PriceJune 2, 2025 | marketbeat.comReplimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingJune 1, 2025 | globenewswire.comTwo Sigma Investments LP Buys 33,346 Shares of Replimune Group, Inc. (NASDAQ:REPL)June 1, 2025 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" from AnalystsJune 1, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Down 5.9% - Time to Sell?May 31, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Up 5.4% - Here's WhyMay 30, 2025 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Nuveen Asset Management LLCMay 30, 2025 | marketbeat.comReplimune to Present at the 2025 Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comHC Wainwright Estimates Replimune Group Q3 EarningsMay 27, 2025 | marketbeat.comLeerink Partnrs Estimates Replimune Group Q1 EarningsMay 27, 2025 | marketbeat.comReplimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA reviewMay 26, 2025 | investing.comEarnings call transcript: Replimune Q1 2025 sees stock drop post-earningsMay 24, 2025 | uk.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModePayment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?By Gabriel Osorio-Mazilli | June 23, 2025View Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?GRPH, LENZ, REPL, and IMTX Company DescriptionsGraphite Bio NASDAQ:GRPHGraphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.Immatics NASDAQ:IMTX$5.46 +0.02 (+0.37%) Closing price 06/25/2025 04:00 PM EasternExtended Trading$5.47 +0.01 (+0.18%) As of 06/25/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.LENZ Therapeutics NASDAQ:LENZ$29.52 -0.26 (-0.87%) Closing price 06/25/2025 04:00 PM EasternExtended Trading$30.20 +0.68 (+2.32%) As of 06/25/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Replimune Group NASDAQ:REPL$9.45 -0.30 (-3.08%) Closing price 06/25/2025 04:00 PM EasternExtended Trading$9.45 0.00 (0.00%) As of 06/25/2025 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides Palantir Stock Hits ATH, But Can the Rally Hold Without Volume? Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
